Literature DB >> 21515751

Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa.

B J Park1, S Shetty, A Ahlquist, A Greenbaum, J L Miller, A Motsi, K McCarthy, N Govender.   

Abstract

Cryptococcal meningitis (CM) is a major cause of death among HIV-infected persons in sub-Saharan Africa. We conducted a study to describe the long-term outcomes during the pre-antiretroviral post-ART therapy period. Enrolled cases were those detected through population-based surveillance in Gauteng Province, South Africa, and diagnosed during March-November 2002 and July-September 2003 from eight large hospitals representing academic, provincial and rural settings. Of 1089 case-patients diagnosed with CM, 721 (70%) survived to discharge. Among the 256 with follow-up information, 154 (60%) were established to have died, 44% of whom died as outpatients. Overall, the 14- and 90-day survival post-diagnosis was 68% and 41%, respectively. On Cox proportional hazards multivariable analysis, severe disease was associated with shorter survival time; having received any antifungal treatment for the cryptococcal episode was associated with increased survival time at follow-up. Although most patients in this cohort survived the initial hospitalization, only 41% were still alive three months after diagnosis, with nearly half of deaths occurring outside a hospital. These data are an important baseline from which to measure effectiveness of public health management of CM in South Africa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515751     DOI: 10.1258/ijsa.2010.010235

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  11 in total

Review 1.  When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!

Authors:  Philip M Grant; Andrew R Zolopa
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

Review 2.  Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.

Authors:  Sarah Lofgren; Mahsa Abassi; Joshua Rhein; David R Boulware
Journal:  Expert Rev Anti Infect Ther       Date:  2017-02-09       Impact factor: 5.091

3.  Multilocus sequence typing of serially collected isolates of Cryptococcus from HIV-infected patients in South Africa.

Authors:  Marelize Van Wyk; Nelesh P Govender; Thomas G Mitchell; Anastasia P Litvintseva
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

4.  AIDS-Related Mycoses: Current Progress in the Field and Future Priorities.

Authors:  Darius Armstrong-James; Tihana Bicanic; Gordon D Brown; Jennifer C Hoving; Graeme Meintjes; Kirsten Nielsen
Journal:  Trends Microbiol       Date:  2017-04-25       Impact factor: 17.079

5.  Survival following screening and preemptive antifungal therapy for subclinical cryptococcal disease in advanced HIV infection.

Authors:  Tariro Azure Makadzange; Admire Hlupeni; Rhoderick Machekano; Kathryn Boyd; Takudzwa Mtisi; Primrose Nyamayaro; Christine Ross; Snighdha Vallabhaneni; Shirish Balachandra; Prosper Chonzi; Chiratidzo Ellen Ndhlovu
Journal:  AIDS       Date:  2021-10-01       Impact factor: 4.632

6.  Accuracy of noninvasive intraocular pressure or optic nerve sheath diameter measurements for predicting elevated intracranial pressure in cryptococcal meningitis.

Authors:  Henry W Nabeta; Nathan C Bahr; Joshua Rhein; Nicholas Fossland; Agnes N Kiragga; David B Meya; Stephen J Dunlop; David R Boulware
Journal:  Open Forum Infect Dis       Date:  2014-10-11       Impact factor: 3.835

7.  Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.

Authors:  David B Meya; Agnes N Kiragga; Elizabeth Nalintya; Bozena M Morawski; Radha Rajasingham; Benjamin J Park; Anthony Mubiru; Jonathan E Kaplan; Yukari C Manabe; David R Boulware
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

8.  Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa.

Authors:  Susan Meiring; Melony Fortuin-de Smidt; Ranmini Kularatne; Halima Dawood; Nelesh P Govender
Journal:  PLoS Negl Trop Dis       Date:  2016-07-28

9.  A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis.

Authors:  James E Scriven; Lisa M Graham; Charlotte Schutz; Thomas J Scriba; Katalin A Wilkinson; Robert J Wilkinson; David R Boulware; Britta C Urban; David G Lalloo; Graeme Meintjes
Journal:  J Infect Dis       Date:  2016-01-14       Impact factor: 5.226

10.  Pathways to care and outcomes among hospitalised HIV-seropositive persons with cryptococcal meningitis in South Africa.

Authors:  Vanessa Quan; Sandra Toro-Silva; Charlotte Sriruttan; Verushka Chetty; Violet Chihota; Sophie Candfield; Anna Vassall; Alison D Grant; Nelesh P Govender
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.